𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The future of peritoneal dialysis: PD in 2010 and beyond

✍ Scribed by John Burkart


Publisher
Wiley (John Wiley & Sons)
Year
2010
Tongue
English
Weight
87 KB
Volume
39
Category
Article
ISSN
0090-2934

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Hyperhomocysteinemia and polymorphisms o
✍ Fernanda Aparecida Domenici; Maria T. I. Vannucchi; Livia M. C. SimΓ΅es-AmbrΓ³sio; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 501 KB

## Abstract Hyperhomocysteinemia has been documented in chronic renal failure (CRF). Premature as well as progressive occlusive vascular disease is common. Mutations or polymorphisms in the gene of the enzyme methylenetetrahydrofolate reductase (MTHFR), as C677T, A1298C and G1793A, are associated w

Efficacy of peritoneal dialysis of tolbu
✍ Takashi Makita; Tetsuya Aiba; Yuki Izuwa; Yukiko Komori; Hiromu Kawasaki; Yuji K πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 118 KB πŸ‘ 1 views

Peritoneal dialysis of a highly protein-bound compound, tolbutamide, was examined in rats to clarify whether the efficacy of the peritoneal dialysis of such compounds increases proportionally as their unbound fractions increase. As expected, it was shown that the tolbutamide concentration of the per

Reducing the formation of glucose degrad
✍ Alina Shapira; Asher Shazman; Yael Ungar; Eyal Shimoni πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 326 KB

## Abstract Peritoneal dialysis (PD) is commonly performed by using preprepared dialysis solutions containing glucose, which are thermally treated to achieve commercial sterilization. A series of glucose degradation products (GDPs) are being formed, which react with the tissue during the dialysis p